Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals reported third-quarter 2026 global net product sales of $185.7 million. The company cited ATEBRIOZ’s recent approval and launch and positive Phase 3 results for its rare liver disease portfolio, including LIVMARLI and brelovitug, as it pursues potential label expansions and approvals. Mirum appointed Rob Myers, M.D., as chief medical officer and repurchased $20.0 million in principal amount of its 4.00% convertible senior subordinated notes due 2029.